Gene and Cellular Therapy Core

$108,335P30FY2013AINIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications & trials

Paper 39710854 Paper 39554138 Paper 39325056 Paper 39261662 Paper 39259241 Paper 38798678 Paper 38626853 Paper 38518770 Paper 38511933 Paper 38408420 Paper 38395539 Paper 38048400 Paper 37977178 Paper 37919520 Paper 37904933 Paper 37841874 Paper 37820006 Paper 37809067 Paper 37803324 Paper 37801341 Paper 37792959 Paper 37788081 Paper 37762169 Paper 37754663 Paper 37730274 Paper 37693528 Paper 37540649 Paper 37520728 Paper 37460960 Paper 37398144 Paper 37368929 Paper 37366057 Paper 37179121 Paper 37093248 Paper 37001280 Paper 36958371 Paper 36943731 Paper 36928413 Paper 36862754 Paper 36757205 Paper 36746875 Paper 36729541 Paper 36629315 Paper 36617220 Paper 36550304 Paper 36514496 Paper 36445393 Paper 36409490 Paper 36332160 Paper 36180125 Paper 36178599 Paper 36172375 Paper 36098370 Paper 35986643 Paper 35951446 Paper 35896987 Paper 35848576 Paper 35840298 Paper 35703769 Paper 35687395 Paper 35655072 Paper 35636071 Paper 35473455 Paper 35467582 Paper 35418685 Paper 35324146 Paper 35273611 Paper 35247913 Paper 35219905 Paper 35217583 Paper 35184308 Paper 35144270 Paper 35065975 Paper 35042956 Paper 35013215 Paper 34995311 Paper 34983952 Paper 34930786 Paper 34908525 Paper 34873092 Paper 34872349 Paper 34834920 Paper 34782761 Paper 34596426 Paper 34509494 Paper 34495777 Paper 34494942 Paper 34462532 Paper 34416157 Paper 34410424 Paper 34403022 Paper 34379273 Paper 34321607 Paper 34315096 Paper 34283885 Paper 34273517 Paper 34161290 Paper 34158342 Paper 34131000 Paper 34023441

Abstract

PROJECT SUMMARY (See instructions): The overall goal of the Gene and Cellular Therapy Core (CoreG) is to provide support for HIV/AIDS-related research requiring stem cells, gene delivery vectors and technical expertise for efficient genetic modification of stem cells. Recent advancements in gene delivery vector systems and stem cell technologies have enabled genetic modification of human hematopoietic stem/progenitor cells (HSPC) to resist HIV infection. The Gene and Cellular Therapy Core is established to meet the increasing demand to promote and facilitate basic and translational research in this area by providing UCLA CFAR investigators and their domestic and international collaborators with highly purified and well characterized human CD34+ HSPC, embryonic stem cells (hESC), induced pluripotent stem cells (iPSC), human fetal tissues and lentiviral vector technologies that enable efficient genetic engineering of stem cells to resist HIV infection. The Core also provides consultation for researchers with limited experience in stem cell and viral vector technologies, in particular early stage investigators. As the use of stem cells and vector technology requires specialized expertise and resources for efficient genetic engineering of different types of stem cells, offering access to these technologies can significantly facilitate and expand the scope of UCLA CFAR research activities. Our services are more cost-effective than utilizing the limited commercial sources. Further value is added by customized technical support available from accessible and knowledgeable core staffs who can work closely with investigators to troubleshoot and optimize experiments, assist with institutional regulatory compliance documents and who are actively engaged in development and application of stem cell and vector technologies. These core services will facilitate translation of stem cell and gene therapy-related HIV research into therapeutic applications.

View original record on NIH RePORTER →